Samsung Bioepis and Boryung Sign Partnership for Bone Disease Treatment Xbrick

Expansion of Domestic Partnership Portfolio

Samsung Bioepis announced on July 2 that it has signed a partnership agreement with Boryung for the domestic sales of "Xbrick," a biosimilar of the bone disease treatment Xgeva.

As the developer, Samsung Bioepis will be responsible for the production and supply of Xbrick, while Boryung will handle exclusive sales and marketing activities in Korea.

Xgeva, developed by Amgen, is a treatment used to prevent skeletal-related events in cancer patients with bone metastases and to treat giant cell tumors of bone. As of 2024, its global sales amount to approximately 3.3 trillion KRW.

Through this agreement, Samsung Bioepis and Boryung have expanded their domestic partnership portfolio to include the Xgeva biosimilar Xbrick, following previous collaborations on the oncology drugs Onbevzi and Samfenet, thereby establishing an even closer cooperative relationship.

In fact, the rapid growth of their partnership products continues, thanks to the excellent product quality of Samsung Bioepis combined with Boryung's expertise in oncology sales and marketing. For example, Onbevzi recorded sales of 45.2 billion KRW last year.

Boryung holds the largest market share in the domestic oncology pharmaceutical sector among Korean companies, operates the largest specialized organization in the country, and offers a wide range of treatment options from oncology supportive care to biosimilars.

Meanwhile, Samsung Bioepis obtained domestic approval for Xbrick in May, and received approval in the United States and Europe in February.

Kim Kyunga, CEO of Samsung Bioepis, stated, "We are pleased to partner with Boryung, a company with expertise in the oncology field, for the domestic sales of Xbrick. We will work closely together to provide more domestic patients with access to biopharmaceutical treatments, leveraging our product capabilities and Boryung's sales competitiveness."

Kim Jungkyun, CEO of Boryung, said, "We are delighted to introduce another high-quality biosimilar developed by Samsung Bioepis. Based on the synergy proven through our existing partnership, we will do our utmost to ensure the early market establishment of Xbrick."